Clinical utility of lanreotide Autogel®in gastroenteropancreatic neuroendocrine tumors.
Somatostatin analogs (SSAs), which were initially used to control hormonal syndromes associated with neuroendocrine neoplasms (NENs), have been successfully proposed as antiproliferative agents, able to control tumor growth in patients affected by gastroenteropancreatic (GEP)-NENs. The development of long-acting formulations of SSAs which require only weekly or monthly injections can improve patient compliance. In particular, lanreotide (LAN) Autogel®, which is a viscous aqueous formulation supplied in ready-to-use prefilled syringes, can be administered every 28-56 days. Since its introduction in the clinical practice, several studies evaluated the clinical utility of LAN Autogel in the medical treatment of GEP-NENs. Although there is no evidence of an overall survival benefit, these studies confirm the efficacy of LAN Autogel in terms of benefit in progression-free survival, and in more than half of cases, a reduction of tumor markers can be observed during treatment with this drug. Moreover, LAN Autogel is widely recognized to be effective in controlling tumor-related symptoms in the majority of patients affected by GEP tumors, especially in patients affected by carcinoid syndrome, improving considerably patients' quality of life.
Department of Medicine, Unit of Endocrinology, Università Cattolica del Sacro Cuore.
Rosa Maria
RM
Paragliola
Department of Medicine, Unit of Endocrinology, Università Cattolica del Sacro Cuore.
Alessandro
A
Prete
Department of Medicine, Unit of Endocrinology, Università Cattolica del Sacro Cuore.
Giampaolo
G
Papi
Department of Systems Medicine, Tor Vergata University, Rome.
Francesco
F
Torino
Department of General Medicine and Endocrine Tumor Unit, San Raffaele Scientific Institute, Milan, Italy.
Andrea
A
Corsello
Department of Medicine, Unit of Endocrinology, Università Cattolica del Sacro Cuore.
Alfredo
A
Pontecorvi
Department of Medicine, Unit of Endocrinology, Università Cattolica del Sacro Cuore.
Salvatore Maria
SM
Corsello
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004339:Drug Compounding; D006801:Humans; D007279:Injections, Subcutaneous; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000378:metabolism; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; D017481:Receptors, Somatostatin; C060347:lanreotide; D013004:Somatostatin
gastroentero-pancreatic neuroendocrine neoplasms; gastroenteropancreatic neuroendocrine tumors; lanreotide Autogel; somatostatin analogs